Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice.

Abstract

Immunotherapy with antibodies against respiratory syncytial virus (RSV) is a treatment option given the absence of any vaccine or other available satisfactory treatment. We selected one of our monoclonal antibodies, RS-348, that is highly neutralizing. We showed that a single peptide (PEP3H) derived from complementarity-determining region 3 (CDR3) of its heavy chain was capable of neutralizing the virus in vitro. When intranasally administered 24 h before challenge, this peptide protected BALB/c mice against RSV lung infection. These results indicate that a single CDR can be effective against RSV infection.

• Authors: C Bourgeois, J B Bour, L S Aho, P Pothier
• Journal: Journal of virology (J Virol) Vol. 72 Issue 1 Pg. 807-10 (Jan 1998) ISSN: 0022-538X [Print] United States
• PMID: 9420291 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Viral
• Immunoglobulin Variable Region

Topics

• Amino Acid Sequence
• Animals
• Antibodies, Monoclonal (administration & dosage, chemistry, genetics)
• Antibodies, Viral (administration & dosage, chemistry, genetics)
• Female
• Immunoglobulin Variable Region (administration & dosage, chemistry, genetics)
• Immunotherapy
• In Vitro Techniques
• Mice
• Mice, Inbred BALB C
• Molecular Sequence Data
• Neutralization Tests
• Respiratory Syncytial Virus Infections (immunology, prevention & control, therapy)
• Respiratory Syncytial Viruses (immunology)